Training Oculo-motor Control to Improve Vision When Using a Preferred Retinal Locus
Launched by RUSSELL L. WOODS · Nov 24, 2022
Trial Information
Current as of May 18, 2025
Unknown status
Keywords
ClinConnect Summary
The purpose of the study is evaluate a potential treatment for loss of (foveal) central vision in both eyes which results in the use of a preferred retinal locus (PRL). The treatment is a series of 16 sessions of about one-hour duration that will involve a mixture of oculomotor control (OMC) training, perceptual training, and scotoma awareness. Two groups will receive the training: (1) central vision loss; and (2) normal sight who will use a simulated scotoma (called control group below).
A single-site, two-way mixed factor, one within-subject and one between-subject, minimal-risk phase-2 ...
Gender
ALL
Eligibility criteria
- • Central Vision Loss Group
- Inclusion Criteria:
- • Bilateral foveal loss that includes the fovea in each eye, as determined through retinal examination
- • fluent in English
- • Cognitive function MoCA (Montreal Cognitive Assessment) test \>20
- • Binocular visual acuity 20/800 or better
- • able to sit for at least an hour
- Exclusion Criteria:
- • speech impediment
- • history of neurological or psychiatric disease
- • inability to provide informed consent
- • inability to follow instructions in English
- • Normal Vision Control Group
- Inclusion Criteria:
- • fluent in English
- • Cognitive function MoCA (Montreal Cognitive Assessment) test \>25
- • Binocular visual acuity 20/40 or better
- • able to sit for at least an hour
- Exclusion Criteria:
- • any ophthalmic disease that might impact on the conduct of the study, especially conditions that cause vision field loss
- • speech impediment
- • history of neurological or psychiatric disease
- • inability to provide informed consent
- • inability to follow instructions in English
About Russell L. Woods
Russell L. Woods is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative trial design and execution. With a focus on integrity and ethical standards, the organization collaborates with leading researchers and healthcare institutions to facilitate cutting-edge studies across various therapeutic areas. Russell L. Woods emphasizes robust data collection and analysis to ensure the reliability of findings, ultimately contributing to the development of effective treatments and therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Russell L Woods, PhD
Principal Investigator
Schepens Eye Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials